Abstract
Eukaryotic cells have highly coordinated mechanisms to control cell proliferation. These include mitogenic signaling and cell cycle control. Cells receive a variety of positive and negative signals from external (growth factors, stresses, etc.) and internal (DNA damage, microtubule integrity, etc.) conditions and must decide to start or cease the cell cycle in response to these signals. Malignant cells arise as a result of a stepwise progression of genetic events that include short-circuited signal transduction and unregulated cell cycle progression. This review focuses on several aspects of cell proliferation control and target molecules for bioprobes which are highly useful in exploring the molecular mechanisms of cell proliferation control. Inhibitors of cell proliferation include a variety of classical cytotoxic compounds such as DNA-damaging agents, membrane-attacking agents, macromolecular synthesis inhibitors, and inhibitors of the respiratory system. Although some of these cytotoxic compounds are useful in analyzing cellular functions, this review focuses on relatively recent inhibitors of cell proliferation, of which targets are involved in the regulation of signal transduction and the cell cycle.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Cantley LC, Auger KR, Carpenter C, Duckworth B, Graziani A, Kapeller R, Soltoff S (1991) Oncogenes and signal transduction. Cell 64:281–302
Pawson T (1995) Protein modules and signalling networks. Nature 373:573–580
Vanhaesebroeck B, Leevers SJ, Panayotou G, Waterfiield MD (1997) Phosphoinositide 3-kinases: a conserved family of signal transducers. Trends Biochem Sci 22:267–272
Akimoto K, Takahashi R, Moriya S, Nishioka N, Takayanagi J, Kimura K, Fukui Y, Osada S, Mizuno K, Hirai S, Kazlauskas A, Ohno S (1996) EGF or PDGF receptors activate atypical PKCX through phosphatidylinositol 3-kinase. EMBO J 15:788–798
Fukui Y, Ihara S, Nagata S (1998) Downstream of phosphatidylinositol–3 kinase, a multifunctional signaling molecule, and its regulation in cell responses. J Biochem 124:1–7
Downward J (1998) Mechanisms and consequences of activation of protein kinase B/ Akt. Cuff Opin Cell Biol 10:262–267
Chung J, Grammer TC, Lemon KP, Kazlauskas A, Blenis J (1994) PDGF- and insulindependent p70s6k activation mediated by phosphatidylinositol-3-OH kinase. Nature 370:71–75
Egan SE, Giddings BW, Brooks MW, Buday L, Sizeland AM, Weinberg RA (1993) Association of Sos Ras exchange protein with Grb2 is implicated in tyrosine kinase signal transduction and transformation. Nature 363:45–51
Buday L, Downward J (1993) Epidermal growth factor regulates p21 ras through the formation of a complex of receptor, Grb2 adapter protein, and Sos nucleotide exchange factor. Cell 73:611–620
Darnell JJ, Kerr IM, Stark GR (1994) Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 264:1415–1421
Avruch J, Zhang X, Kyriakis JM (1994) Raf meets Ras: completing the framework of a signal transduction pathway. Trends Biochem Sci 19:279–283
Morrison DK, Cutler Jr R (1997) The complexity of Raf-1 regulation. Curr Opin Cell Biol 9:174–179
Vojtek AB, Hollenberg SM, Cooper JA (1993) Mammalian Ras interacts directly with the serine/threonine kinase Raf. Cell 74:205–214
Robinson MJ, Cobb MH (1997) Mitogen-activated protein kinase pathways. Curr Opin Cell Biol 9:180–186
Kyriakis JM, Banerjee P, Nikolakaki E, Dai T, Rubie EA, Ahmad MF, Avruch J, Woodgett JR (1994) The stress-activated protein kinase subfamily of c-Jun kinases. Nature 369:156–160
Han J, Lee JD, Bibbs L, Ulevitch RJ (1994) A MAP kinase targeted by endotoxin and hyperosmolarity in mammalian cells. Science 265:808–811
Minden A, Karin M (1997) Regulation and function of the JNK subgroup of MAP kinases. Biochim Biophys Acta 1333:F85–F104
Keating MT, Escobedo JA, Williams LT (1988) Ligand activation causes a phosphorylation-dependent change in platelet-derived growth factor receptor conformation. J Biol Chem 263:12805–12808
Uehara Y, Fukazawa H (1991) Use and selectivity of herbimycin A as inhibitor of protein-tyrosine kinases. Methods Enzymol 201:370–379
Akiyama T, Ishida J, Nakagawa S, Ogawara H, Watanabe S-i, Itoh N, Shibuya M, Fukami Y (1987) Genistein, a specific inhibitor of tyrosine-specific protein kinases. J Biol Chem 262:5592–5595
Umezawa K, Hori T, Tajima H, Imoto M, Isshiki K, Takeuchi T (1990) Inhibition of epidermal growth factor-induced DNA synthesis by tyrosine kinase inhibitors. FEBS Lett 260:198–200
Gazit A, Yaish P, Gilon C, Levitzki A (1989) Tyrphostins I: synthesis and biological activity of protein tyrosine kinase inhibitors. J Med Chem 32:2344–2352
Fukazawa H, Mizuno S, Uehara Y (1990) Effects of herbimycin A and various SH-reagents on p60v-src kinase activity in vitro. Biochem Biophys Res Commun 173:276–282
Whitesell L, Mimnaugh EG, De CB, Myers CE, Neckers LM (1994) Inhibition of heat shock protein Hsp90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation. Proc Natl Acad Sci USA 91:8324–8328
Imoto M, Kakeya H, Sawa T, Hayashi C, Hamada M, Takeuchi T, Umezawa K (1993) Dephostatin, a novel protein tyrosine phosphatase inhibitor produced by Streptomyces. I. Taxonomy, isolation, and characterization. J Antibiot (Tokyo) 46:1342–1346
Hamaguchi T, Sudo T, Osada H (1995) RK-682, a potent inhibitor of tyrosine phosphatase, arrested the mammalian cell cycle progression at GI phase. FEBS Lett 372:54–58
Gescher A (1998) Analogs of staurosporine: potential anticancer drugs? Gen Pharmacol 31:721–728
Kawakami K, Futami H, Takahara J, Yamaguchi K (1996) UCN-01, 7-hydroxylstaurosporine, inhibits kinase activity of cyclin- dependent kinases and reduces the phosphorylation of the retinoblastoma susceptibility gene product in A549 human lung cancer cell line. Biochem Biophys Res Commun 219:778–783
Kobayashi E, Nakano H, Morimoto M, Tamaoki T (1989) Calphostin C (UCN-1028C), a novel microbial compound, is a highly potent and specific inhibitor of protein kinase C. Biochem Biophys Res Commun 159:548–553
Daniel LW, Civoli F, Rogers MA, Smitherman PK, Raju PA, Roederer M (1995) ET-18-OCH3 inhibits nuclear factor-κB activation by 12–0- tetradecanoylphorbol-13-acetate but not by tumor necrosis factor-alpha or interleukin 1α. Cancer Res 55:4844–4849
Froscio M, Murray AW, Hurst NP (1989) Inhibition of protein kinase C activity by the antirheumatic drug auranofin. Biochem Pharmacol 38:2087–2089
Imoto M, Taniguchi Y, Umezawa K (1992) Inhibition of CDP-DG: inositol transferase by inostamycin. J Biochem (Tokyo) 112:299–302
Deguchi A, Imoto M, Umezawa K (1996) Inhibition of G1 cyclin expression in normal rat kidney cells by inostamycin, a phosphatidylinositol synthesis inhibitor. J Biochem (Tokyo) 120:1118–1122
Kuo CJ, Chung J, Fiorentino DF, Flanagan WM, Blenis J, Crabtree GR (1992) Rapamycin selectively inhibits interleukin-2 activation of p70 S6 kinase. Nature 358:70–73
Chung J, Kuo CJ, Crabtree GR, Blenis J (1992) Rapamycin-FKBP specifically blocks growth-dependent activation of and signaling by the 70 kd S6 protein kinase. Cell 69:1227–1236
Kunz J, Henriquez R, Schneider U, Deuter-Reinhard M, Movva NR, Hall MN (1993) Target of rapamycin in yeast, TOR2, is an essential phosphatidylinositol kinase homolog required for G1 progression. Cell 73:585–596
Brown EJ, Albers MW, Shin TB, Ichikawa K, Keith CT, Lane WS, Schreiber SL (1994) A mammalian protein targeted by G1-arresting rapamycin-receptor complex. Nature 369:756–758
Brown EJ, Beal PA, Keith CT, Chen J, Shin TB, Schreiber SL (1995) Control of p70 s6 kinase by kinase activity of FRAP in vivo. Nature 377:441–446
Yano H, Nakanishi S, Kimura K, Hanai N, Saitoh Y, Fukui Y, Nonomura Y, Matsuda Y (1993) Inhibition of histamine secretion by wortmannin through the blockade of phosphatidylinositol 3-kinase in RBL-2H3 cells. J Biol Chem 268:25846–25856
Muise-Helmericks RC, Grimes HL, Bellacosa A, Malstrom SE, Tsichlis PN, Rosen N (1998) Cyclin D expression is controlled post-transcriptionally via a phosphatidylinositol 3-kinase/Akt-dependent pathway. J Biol Chem 273:29864–29872
Hara M, Akasaka K, Akinaga S, Okabe M, Nakano H, Gomez R, Wood D, Uh M, Tamanoi F(1993) Identification of Ras farnesyltransferase inhibitors by microbial screening. Proc Natl Acad Sci USA 90:2281–2285
Kohl NE, Mosser SD, deSolms SJ, Giuliani EA, Pompliano DL, Graham SL, Smith RL, Scolnick EM, Oliff A, Gibbs JB (1993) Selective inhibition of ras-dependent transformation by a farnesyltransferase inhibitor. Science 260:1934–1937
James GL, Goldstein JL, Brown MS, Rawson TE, Somers TC, McDowell RS, Crowley CW, Lucas BK, Levinson AD, Marsters JJC (1993) Benzodiazepine peptidomimetics: potent inhibitors of Ras farnesylation in animal cells. Science 260:1937–1942
Keyomarsi K, Sandoval L, Band V, Pardee AB (1991) Synchronization of tumor and normal cells from GI to multiple cell cycles by lovastatin. Cancer Res 51:3602–3609
DeClue JE, Vass WC, Papageorge AG, Lowy DR, Willumsen BM (1991) Inhibition of cell growth by lovastatin is independent of ras function. Cancer Res 51:712–717
Vogt A, Qian Y, McGuire TF, Hamilton AD, Sebti SM (1996) Protein geranylgeranylation, not farnesylation, is required for the G1 to S phase transition in mouse fibroblasts. Oncogene 13:1991–1999
Adnane J, Bizouarn FA, Qian Y, Hamilton AD, Sebti SM (1998) p21(WAF1/CIPI) is upregulated by the geranylgeranyltransferase I inhibitor GGTI-298 through a transforming growth factor beta- and Spl- responsive element: involvement of the small GTPase rhoA. Mol Cell Biol 18:6962–6970
Kwon HJ, Yoshida M, Fukui Y, Horinouchi S, Beppu T (1992) Potent and specific inhibition of p60v-src protein kinase both in vivo and in vitro by radicicol. Cancer Res 52:6926–6930
Ki SW, Kasahara K, Kwon HJ, Eishima J, Takesako K, Cooper JA, Yoshida M, Horinouchi S (1998) Identification of radicicol as an inhibitor of in vivo Ras/Raf interaction by the yeast two-hybrid screen system. J Antibiot 51:936–944
Roe SM, Prodromou C, O’Brien R, Ladbury JE, Piper PW, Pearl LH (1999) Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumor antibiotics radicicol and geldanamycin. J Med Chem 42:260–266
Alessi DR, Cuenda A, Cohen P, Dudley DT, Saltiel AR (1995) PD 098059 is a specific inhibitor of the activation of mitogen- activated protein kinase kinase in vitro and in vivo. J Biol Chem 270: 27489–94
Cuenda A, Rouse J, Doza YN, Meier R, Cohen P, Gallagher TF, Young PR, Lee JC (1995) SB203580 is a specific inhibitor of a MAP kinase homologue which is stimulated by cellular stresses and interleukin-1. FEBS Lett 364: 229–233
Fukuda M, Gotoh I, Adachi M, Gotoh Y, Nishida E (1997) A novel regulatory mechanism in the mitogen-activated protein (MAP) kinase cascade. Role of nuclear export signal of MAP kinase kinase. J Biol Chem 272: 32642–32648
Dingwall C, Laskey RA (1991) Nuclear targeting sequences: a consensus? Trends Biochem Sci 16: 478–481
Görlich D, Vogel F, Mills AD, Hartmann E, Laskey RA (1995) Distinct functions for the two importin subunits in nuclear protein import. Nature 377: 246–248
Siomi H, Dreyfuss G (1995) A nuclear localization domain in the hnRNP Al protein. J Cell Biol 129: 551–560
Bischoff FR, Ponstingl H(1991) Catalysis of guanine nucleotide exchange on Ran by the mitotic regulator RCCl. Nature 354: 80–82
Bischoff FR, Krebber H, Kemph T, Hermes I, Ponstingl H (1995) Human RanGTPase activating protein RanGAP1 is a homolog of yeast RNAIp involved in messenger RNA processing and transport. Proc Natl Acad Sci USA 92: 1749–1753
Izaurralde E, Kutay U, von Kobbe C, Mattaj IW, Gorlick D (1997) The asymmetric distribution of the constituents of the Ran system is essential for transport into and out of the nucleus. EMBO J 16: 6535–6547
Fischer U, Huber J, Boelens WC, Mattaj IW, Lührmann R (1995) The HIV-1 Rev activation domain is a nuclear export signal that accesses an export pathway used by specific cellular RNAs. Cell 82: 475–483
Wen W, Meinkoth JL, Tsien RY, Taylor SS (1995) Identification of a signal of rapid export of proteins from the nucleus. Cell 82: 463–473
Adachi Y, Yanagida M (1989) Higher order chromosome structure is affected by coldsensitive mutations in a Schizosaccharomyces pombe gene crm1 + which encodes a 115-kD protein preferentially localized in the nucleus and at its periphery. J Cell Biol 108: 1159–1207
Engel K, Kotlyarov A, Gaestel M (1998) Leptomycin B-sensitive nuclear export of MAPKAP kinase 2. EMBO J 17: 3363–3371
Wasylyk B, Hagman J, Gutierrez-Hartmann A (1998) Ets transcription factors: nuclear effectors of the Ras-MAP-kinase signaling pathway. Trends Biochem Sci 23: 213–216
Karin M, Liu Zg, Zandi E (1997) AP-1 function and regulation. Curr Opin Cell Biol 9: 240–246
Montminy M (1997) Transcriptional regulation by cyclic AMP. Annu Rev Biochem 66: 807–822
Turner BM (1991) Histone acetylation and control of gene expression. J Cell Sci 99: 13–20
Taunton J, Hassig CA, Schreiber SL (1996) A mammalian histone deacetylase related to the yeast transcriptional regulator Rpd3p. Science 272: 408–411
Kijima M, Yoshida M, Sugita K, Horinouchi S, Beppu T (1993) Trapoxin, an antitumor cyclic tetrapeptide, is an irreversible inhibitor of mammalian histone deacetylase. J Biol Chem 268: 22429–22435
Wade PA, Pruss D, Wolfe AP (1997) Histone acetylation: chromatin in action. Trends Biochem Sci 22: 128–132
Torchia J, Glass C, Rosenfeld MG (1998) Co-activators and co-repressors in the integration of transcriptional responses. Curr Opin Cell Biol 10: 373–383
Janknecht R, Hunter T (1996) A growing coactivator network. Nature 383: 22–23
Yang Xi, Ogryzko VV, Nishikawa J, Howard BH, Nakatani Y (1996) A p300/CBP-associated factor that competes with the adenoviral oncoprotein EIA. Nature 382: 319–324
Petrij F, Giles RH, Dauwerse HG, Saris JJ, Hennekam RCM, Masuno M, Tommerup N, van Ommen G-JB, Goodman RH, Peters DJM, Breuning MH (1995) Rubinstein-Taybi syndrome caused by mutations in the transcriptional co-activator CBP. Nature 376: 348–351
Gu W, Roeder RG (1997) Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell 90: 595–606
Boyes J, Byfield P, Nakatani Y, Ogryzko V (1998) Regulation of activity of the transcription factor GATA-1 by acetylation. Nature 396: 594–598
Nishi K, Yoshida M, Fujiwara D, Nishikawa M, Horinouchi S, Beppu T (1994) Leptomycin B targets a regulatory cascade of crml, a fission yeast nuclear protein, involved in control of higher order chromosome structure and gene expression. J Biol Chem 269: 6320–6324
Wolff B, Sanglier J-J, Wang Y (1997) Leptomycin B is an inhibitor of nuclear export: inhibition of nucleo-cytoplasmic translocation of the human immunodeficiency virus type 1 (HIV-1) Rev protein and Rev-dependent mRNA. Chem Biol 4: 139–147
Fornerod M, Deursen Jv, Baal Sv, Reynolds A, Davis D, Murti KG, Fransen J, Grosveld G (1997) The human homologue of yeast CRM 1 is in a dynamic subcomplex with CAN/ Nup214 and a novel nuclear pore component Nup 88. EMBO J 16: 807–816
Kudo N, Khochbin S, Nishi K, Kitano K, Yanagida M, Yoshida M, Horinouchi S (1997) Molecular cloning and cell cycle-dependent expression of mammalian CRM 1, a protein involved in nuclear export of proteins. J Biol Chem 272: 29742–29751
Fornerod M, Ohno M, Yoshida M, Mattaj IW (1997) CRMI is an export receptor for leucine-rich nuclear export signals. Cell 90: 1051–1060
Stade K, Ford CS, Guthrie C, Weis K (1997) Exportin 1 (Crmlp) is an essential nuclear export factor. Cell 90: 1041–1050
Fukuda M, Asano S, Nakamura T, Adachi M, Yoshida M, Yanagida M, Nishida E (1997) CRM1 is responsible for intracellular transport mediated by the nuclear export signal. Nature 390: 308–311
Kudo N, Wolff B, Sekimoto T, Schreiner EP, Yoneda Y, Yanagida M, Horinouchi S, Yoshida M (1998) Leptomycin B inhibition of signal-mediated nuclear export by direct binding to CRM 1. Exp Cell Res 242: 540–547
Kudo N, Matsumori N, Taoka H, Fujiwara D, Schreiner EP, Wolff B, Yoshida M, Horinouchi S (1999) Leptomycin B inactivates CRMI/exportin 1 by covalent modification at a cysteine residue in the central conserved region. Proc Natl Acad Sci USA 96: 9112–9117
Goto M, Masegi M, Yamauchi T, Chiba K, Kuboi Y, Harada K, Naruse N (1998) K1115 A, a new anthraquinone derivative that inhibits the binding of activator protein-1 (AP-1) to its recognition sites. I. Biological activities. J Antibiot 51: 539–544
Sakai Y, Yoshida T, Tsujita T, Ochiai K, Agatsuma T, Saitoh Y, Tanaka F, Akiyama T, Akinaga S, Mizukami T (1997) GE3, a novel hexadepsipeptide antitumor antibiotic, produced by Streptomyces sp. I. Taxonomy, production, isolation, physico-chemical properties, and biological activities. J Antibiot 50: 659–664
Yoshida M, Horinouchi S, Beppu T (1995) Trichostatin A and trapoxin: novel chemical probes for the role of histone acetylation in chromatin structure and function. Bio Essays 17: 423–430
Yoshida M, Kijima M, Akita M, Beppu T (1990) Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J Biol Chem 265: 17174–17179
Nan X, Ng HH, Johnson CA, Laherty CD, Turner BM, Eisenman RN, Bird A (1998) Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature 393: 386–389
Nakajima H, Kim YB, Terano H, Yoshida M, Horinouchi S (1998) FR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor. Exp Cell Res 241: 126–133
Kwon HJ, Owa T, Hassig CA, Shimada J, Schreiber SL (1998) Depudecin induces morphological reversion of transformed fibroblasts via the inhibition of histone deacetylase. Proc Natl Acad Sci USA 95: 3356–3361
Kim YB, Lee K-H, Sugita K, Yoshida M, Horinouchi S (1999) Oxamflatin is a novel antitumor compound that inhibits mammalian histone deacetylase. Oncogene 18: 2461–2470
Pardee AB (1989) GI events and regulation of cell proliferation. Science 246: 603–608
Norbury C, Nurse P (1992) Animal cell cycles and their control. Annu Rev Biochem 61: 441–470
Lee MG, Nurse P (1987) Complementation used to clone a human homologue of the fission yeast cell cycle control gene cdc2. Nature 327: 31–35
Morgan DO (1995) Principles of CDK regulation. Nature 374: 131–134
Lukas J, Bartkova J, Rohde M, Strauss M, Bartek J (1995) Cyclin D1 is dispensable for G1 control in retinoblastoma gene-deficient cells independently of cdk4 activity. Mol Cell Biol 15: 2600–2611
Sherr CJ (1993) Mammalian G1 cyclins. Cell 73: 1059–1065
Hilt W, Wolf DH (1996) Proteasomes: destruction as a programme. Trends Biochem Sci 21: 96–102
Solomon MJ (1993) Activation of the various cyclin/cdc2 protein kinases. Curr Opin Cell Biol 5:180–186
Nurse P (1990) Universal control mechanism regulating onset of M-phase. Nature 344:503–508
Nigg EA (1995) Cyclin-dependent protein kinases: key regulators of the eukaryotic cell cycle. Bioessays 17:471–480
Yaffe MB, Schutkowski M, Shen M, Zhou XZ, Stukenberg PT, Rahfeld JU, Xu J, Kuang J, Kirschner MW, Fischer G, Cantley LC, Lu KP (1997) Sequence-specific and phosphorylation-dependent proline isomerization: a potential mitotic regulatory mechanism. Science 278:1957–1960
Shen M, Stukenberg PT, Kirschner MW, Lu KP (1998) The essential mitotic peptidylprolyl isomerase Pinl binds and regulates mitosis-specific phosphoproteins. Genes Dev 12:706–720
Hennig L, Christner C, Kipping M, Schelbert B, Rucknagel KP, Grabley S, Kullertz G, Fischer G (1998) Selective inactivation of parvulin-like peptidyl-prolyl cis/trans isomerases by juglone. Biochemistry 37:5953–5960
Hagting A, Karlsson C, Clute P, Jackman M, Pines J (1998) MPF localization is controlled by nuclear export. EMBO J 17:4127–4138
Hunter T, Pines J (1994) Cyclins and cancer. II: Cyclin D and CDK inhibitors come of age. Cell 79:573–582
Elledge SJ, Harper JW (1994) Cdk inhibitors: on the threshold of checkpoints and development. Curr Opin Cell Biol 6:847–852
Grana X, Reddy EP (1995) Cell cycle control in mammalian cells: role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CKIs). Oncogene 11:211–219
Kawada M, Yamagoe S, Murakami Y, Suzuki K, Mizuno S, Uehara Y (1997) Induction of p27Kipl degradation and anchorage independence by Ras through the MAP kinase signaling pathway. Oncogene 15:629–637
Serrano M, Hannon GJ, Beach D (1993) A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 366:704–707
Lukas J, Parry D, Aagaard L, Mann DJ, Bartkova J, Strauss M, Peters G, Bartek J (1995) Retinoblastoma-protein-dependent cell-cycle inhibition by the tumour suppressor p16. Nature 375:503–506
Kamijo T, Zindy F, Roussel MF, Quelle DE, Downing JR, Ashmun RA, Grosveld G, Sherr CJ (1997) Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF. Cell 91:649–659
Bates S, Phillips AC, Clark PA, Stott F, Peters G, Ludwig RL, Vousden KH (1998) p14ARF links the tumour suppressors RB and p53. Nature 395:124–125
Zhang Y, Xiong Y, Yarbrough WG (1998) ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 92:725–734
Bartek J, Bartkova J, Lukas J (1996) The retinoblastoma protein pathway and the restriction point. Curr Opin Cell Biol 8:805–814
Brehm A, Miska EA, McCance DJ, Reid JL, Bannister AJ, Kouzarides T (1998) Retinoblastoma protein recruits histone deacetylase to repress transcription. Nature 391:597–601
Magnaghi JL, Groisman R, Naguibneva I, Robin P, Lorain S, Le VJ, Troalen F, Trouche D, Harel BA (1998) Retinoblastoma protein represses transcription by recruiting a histone deacetylase. Nature 391:601–605
Kitagawa M, Okabe T, Ogino H, Matsumoto H, Suzuki-Takahashi I, Kokubo T, Higashi H, Saitoh S, Taya Y, Yasuda H, Ohba Y, Nishimura S, Tanaka N, Okuyama A (1993) Butyrolactone I, a selective inhibitor of cdk2 and cdc2 kinase. Oncogene 8:2425–2432
Abe K, Yoshida M, Usui T, Horinouchi S, Beppu T (1991) Highly synchronous culture of fibroblasts from G2 block caused by staurosporine, a potent inhibitor of protein kinases. Exp Cell Res 192:122–127
Schnier JB, Nishi K, Goodrich DW, Bradbury EM (1996) G1 arrest and down-regulation of cyclin E/cyclin-dependent kinase 2 by the protein kinase inhibitor staurosporine are dependent on the retinoblastoma protein in the bladder carcinoma cell line 5637. Proc Natl Acad Sci USA 93:5941–5946
Meijer L, Borgne A, Mulner 0, Chong JP, Blow JJ, Inagaki N, Inagaki M, Delcros JG, Moulinoux JP (1997) Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. Eur J Biochem 243:527–536
Kakeya H, Onose R, Liu PC, Onozawa C, Matsumura F, Osada H (1998) Inhibition of cyclin D1 expression and phosphorylation of retinoblastoma protein by phosmidosine, a nucleotide antibiotic. Cancer Res 58:704–710
Takuwa N, Fukui Y, Takuwa Y (1999) Cyclin D1 expression mediated by phosphatidylinositol 3-kinase through mTOR-p70(S6K)-independent signaling in growth factor-stimulated NIH 3T3 fibroblasts. Mol Cell Biol 19:1346–1358
Gorospe M, Liu Y, Xu Q, Chrest FJ, Holbrook NJ (1996) Inhibition of G1 cyclindependent kinase activity during growth arrest of human breast carcinoma cells by prostaglandin A2. Mol Cell Biol 16:762–770
Fenteany G, Standaert RF, Lane WS, Choi S, Corey EJ, Schreiber SL(1995) Inhibition of proteasome activities and subunit-specific amino-terminal threonine modification by lactacystin. Science 268:726–731
Lane DP (1992) Cancer. p53, guardian of the genome. Nature 358:15–16.
Shieh SY, Ikeda M, Taya Y, Prives C (1997) DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell 91:325–334
Banin S, Moyal L, Shieh S, Taya Y, Anderson CW, Chessa L, Smorodinsky NI, Prives C, Reiss Y, Shiloh Y, Ziv Y (1998) Enhanced phosphorylation of p53 by ATM in response to DNA damage. Science 281:1674–1677
Stommel JM, Marchenko ND, Jimenez GS, Moll UM, Hope TJ, Wahl GM (1999) A leucine-rich nuclear export signal in the p53 tetramerization domain: regulation of subcellular localization and p53 activity by NES masking. EMBO J 18:1660–1672
Lopez-Girona A, Furnari B, Mondesert 0, Russell P (1999) Nuclear localization of Cdc25 is regulated by DNA damage and a 14–3-3 protein. Nature 397:172–175
Yang J, Winkler K, Yoshida M, Kornbluth S (1999) Maintenance of G2 arrest in the Xenopus oocyte: A role for 14–3-3-mediated inhibition of Cdc25 nuclear import. EMBO J 18:2174–2183
Kumagai A, Guo Z, Emami KH, Wang SX, Dunphy WG (1998) The Xenopus Chkl protein kinase mediates a caffeine-sensitive pathway of checkpoint control in cell-free extracts. J Cell Biol 142:1559–1569
Schlegel R, Pardee AB (1986) Caffeine-induced uncoupling of mitosis from the completion of DNA replication in mammalian cells. Science 232:1264–1266
Andreassen PR, Margolis RL (1992) 2-Aminopurine overrides multiple cell cycle checkpoints in BHK cells. Proc Nati Acad Sci USA 89:2272–2726
Yoshida M, Usui T, Tsujimura K, Inagaki M, Beppu T, Horinouchi S (1997) Biochemical differences between staurosporine-induced apoptosis and premature mitosis. Exp Cell Res 232:225–239
Shao RG, Cao CX, Shimizu T, O’Connor PM, Kohn KW, Pommier Y (1997) Abrogation of an S-phase checkpoint and potentiation of camptothecin cytotoxicity by 7-hydroxystaurosporine (UCN-01) in human cancer cell lines, possibly influenced by p53 function. Cancer Res 57:4029–4035
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2000 Springer-Verlag Tokyo
About this chapter
Cite this chapter
Yoshida, M. (2000). Cell Proliferation: From Signal Transduction to Cell Cycle. In: Osada, H. (eds) Bioprobes. Springer, Tokyo. https://doi.org/10.1007/978-4-431-65927-3_2
Download citation
DOI: https://doi.org/10.1007/978-4-431-65927-3_2
Publisher Name: Springer, Tokyo
Print ISBN: 978-4-431-65929-7
Online ISBN: 978-4-431-65927-3
eBook Packages: Springer Book Archive